TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01169155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Alarm Stimuli
Description: See arm descriptions for information about the smoke alarm stimuli interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Alarm Stimuli
Description: See arm descriptions for information about the smoke alarm stimuli interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Alarm Stimuli
Description: See arm descriptions for information about the smoke alarm stimuli interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Alarm Stimuli
Description: See arm descriptions for information about the smoke alarm stimuli interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Alarm Stimuli
Description: See arm descriptions for information about the smoke alarm stimuli interventions.
Study: NCT01620242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2 every 3 weeks by IV administration
Study: NCT04170322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thin pvc gastric tube
Description: a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thick silicone gastric tube
Description: a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
Study: NCT03496428

Intervention type: DEVICE
Group type: OTHER
Intervention: Dental implant impressions- Different Techniques
Description: Assessment of soft tissues changes with different techniques
Study: NCT00343889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-PRP~T vaccine + OPV
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib™ + OPV vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: Oral co-administered with study vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Polio Vaccine
Description: Oral co-administered with study vaccine
Study: NCT04276428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC.
Study: NCT00492752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: multikinase inhibitor; Sorafenib 400 mg (orally) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (orally) twice daily
Study: NCT02691442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5%
Description: The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5% + epinephrin 1/200000
Description: The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
Study: NCT03290833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
Study: NCT04514523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QBSAfe Toolkit
Description: The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
Study: NCT03446950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Surgery
Description: Patients will undergo elective surgery on vagina or bladder

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Surgery
Description: Patients will undergo elective surgery on vagina or bladder
Study: NCT03275194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
Study: NCT02260115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LABS™
Description: hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Surgical Control
Description: Surgery only
Study: NCT04161430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108; Placebo matching sitagliptin
Description: Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching DBPR108; Sitagliptin; DBPR108
Description: Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108
Description: Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks.
Study: NCT03816930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical cord usage
Description: Due to the retraction procedures, same preparation conditions will be obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical cord usage
Description: Due to the retraction procedures, same preparation conditions will be obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical cord usage
Description: Due to the retraction procedures, same preparation conditions will be obtained.
Study: NCT02550184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focused ultrasonographic examination.
Description: Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused ultrasonographic examination.
Description: Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
Study: NCT01541475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion, Escitalopram
Description: Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
Study: NCT00490451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
Study: NCT02346162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management
Description: Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI \</=25, and when pregnant, weight gain within IOM guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
Study: NCT00950664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport® (abobotulinumtoxinA)
Description: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport® (abobotulinumtoxinA)
Description: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox® (onabotulinumtoxinA)
Description: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox® (onabotulinumtoxinA)
Description: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
Study: NCT02351505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01582425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: oral
Study: NCT01083303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weaning Preterm Infants from an incubator
Description: Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weaning Preterm Infants from an incubator
Description: Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
Study: NCT03269045

Intervention type: DRUG
Group type: OTHER
Intervention: ORL-1B
Description: Oral ORL-1B
Study: NCT03173833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAGO questionnaire outcome
Description: Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
Study: NCT04209751

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool removal
Description: Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
Study: NCT04458298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: OP-101 infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: OP-101 infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: OP-101 infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: OP-101 infusion will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo infusion will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo infusion will be administered intravenously.
Study: NCT01317862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical foley catheter, Prostaglandins
Description: 16 French foley catheter 10mg dinoprostone vaginal insert

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical foley catheter, Prostaglandins
Description: 16 French foley catheter 10mg dinoprostone vaginal insert
Study: NCT00050609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet taken by mouth once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet taken by mouth once a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day for 8 weeks
Study: NCT03000907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Diet and physical exercises
Study: NCT05309798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening Fasting
Description: Participants will undertake acute evening fasting (feeding between 8am-4pm) for one day. After which they will attend the laboratory, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Fasting
Description: Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm). After which, participants will visit the laboratory the following day, after a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm). After which, participants will visit the laboratory the following day, after a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
Study: NCT03831841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise programe
Description: An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
Study: NCT01508702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad
Description: Tablets, 400 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo QD
Study: NCT01202929

Intervention type: PROCEDURE
Intervention: High Resolution Manometry
Description: High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.

Intervention type: PROCEDURE
Intervention: High Resolution Manometry
Description: High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.

Intervention type: PROCEDURE
Intervention: High Resolution Manometry
Description: High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
Study: NCT04845100

Intervention type: OTHER
Group type: OTHER
Intervention: Animal Assisted Activity Program
Description: Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Assisted Activity Program
Description: Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)
Study: NCT03222206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Medicate placebo 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month
Study: NCT02255422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone capsules, 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 160 mg
Study: NCT04967937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening, resistance exercise, plyometric and dynamic movement training
Description: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training.
Study: NCT03536988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAMIS-IPAA
Description: In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap-IPAA
Description: In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
Study: NCT01950000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01565733

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
Study: NCT02595151

Intervention type: DEVICE
Intervention: CLE
Description: The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.

Intervention type: DEVICE
Intervention: CLE
Description: The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
Study: NCT04539639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
Study: NCT05133011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue base reduction surgery
Description: Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue base reduction surgery
Description: Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study
Study: NCT00651066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1
Description: 3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2
Description: 3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
Study: NCT04319133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Doing fasting 2 days a week within 8 weeks
Study: NCT04511247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagicTouch PTA Sirolimus drug coated balloon
Description: For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA balloon
Description: For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
Study: NCT03050242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
Study: NCT03476499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging (NIR) device
Description: Handheld near infrared multispectral imaging device with custom software.